Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $40,646 - $94,213
13,459 Added 50.47%
40,126 $232,000
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $21,389 - $41,140
10,234 Added 62.28%
26,667 $86,000
Q1 2022

May 16, 2022

BUY
$3.45 - $14.99 $56,693 - $246,330
16,433 New
16,433 $62,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $532M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Occudo Quantitative Strategies LP Portfolio

Follow Occudo Quantitative Strategies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

News

Stay updated on Occudo Quantitative Strategies LP with notifications on news.